The companies behind the molecules
Pharma, biotech & telehealth in peptide therapy
The firms whose decisions shape peptide-therapy access — GLP-1 manufacturers, compounding telehealth players, clinical-stage challengers, and a few private-side longevity outliers. Live ticker for public names; brief, plain-language descriptions for everyone.
Prices via Yahoo Finance, refreshed every 5 minutes. We don't give investment advice — see funding & affiliate disclosure.
- LLY/NYSE
Eli Lilly and Company
Indianapolis, USA
price unavailable
- NVO/NYSE
Novo Nordisk
Bagsværd, Denmark
price unavailable
- HIMS/NYSE
Hims & Hers Health
San Francisco, USA
price unavailable
- PFE/NYSE
Pfizer
New York, USA
price unavailable
- AMGN/NASDAQ
Amgen
Thousand Oaks, USA
price unavailable
- RHHBY/OTC
Roche
Basel, Switzerland
price unavailable
- VKTX/NASDAQ
Viking Therapeutics
San Diego, USA
price unavailable
- GPCR/NASDAQ
Structure Therapeutics
South San Francisco, USA
price unavailable
- ALT/NASDAQ
Altimmune
Gaithersburg, USA
price unavailable
- UBX/NASDAQ
Unity Biotechnology
South San Francisco, USA
price unavailable
- Private
Blueprint (Bryan Johnson)
Venice, USA
Bootstrapped — Bryan Johnson personal balance sheet
- Private
ProxofIM
Groningen, Netherlands
Seed / pre-clinical — fundraising disclosed in academic publications